ArticleAntimicrobial agents and chemotherapy2015
Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 61 citations in OpenAlex.
- Mycobacterium intracellulare M.i.198-A Promising Strain for Studying Pathogenesis of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD).Microbiology and immunology · 2026Review
- Multipronged Cell Wall-Targeting Converts Ineffective Antibiotics into a Potent Regimen against Mycobacterium abscessus.ACS infectious diseases · 2026Article
- Strain-dependent disease progression and necrotizing granuloma formation in a murine model induced by virulent strains ofMicrobiology spectrum · 2026Article
- Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse.The Journal of infectious diseases · 2026Article
- NTM-host matched infection models for the classification of drug efficacy against rapid and slow growing nontuberculous mycobacteria species.Scientific reports · 2026Article
- Efficacy of drug regimens containing omadacycline in a murine model ofFrontiers in microbiology · 2026Article
- Virulence ofVeterinary medicine international · 2026Article
- Immunopathological outcomes are isolate dependent in chronic Mycobacterium avium complex pulmonary disease.Disease models & mechanisms · 2026Article
- The function of TLR2 and the microbiome in macrophage-dependent dissemination of nontuberculous mycobacterial gut infection.International journal of biological sciences · 2026Article
- Efficacies of sequenced monotherapies ofbioRxiv : the preprint server for biology · 2025Article
- Immunity AgainstVaccines · 2025Article
- The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronicAntimicrobial agents and chemotherapy · 2025Article
- C3HeB/FeJ mice with chronicMycobacteria (London, England) · 2025Article
- Regimen comprising clarithromycin, clofazimine and bedaquiline is more efficacious than monotherapy in a mouse model of chronicbioRxiv : the preprint server for biology · 2024Article
- Assays for AssessingPathogens (Basel, Switzerland) · 2024Article
- Human mesenchymal stromal cells inhibitThorax · 2024Article
- Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.Tuberculosis (Edinburgh, Scotland) · 2024Review
- Protein-energy restriction-induced lipid metabolism disruption causes stable-to-progressive disease shift in Mycobacterium avium-infected female mice.EBioMedicine · 2024Article
- Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection.PloS one · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
The Mycobacterium avium complex is the most common cause of nontuberculous mycobacterial lung disease worldwide; yet, an optimal treatment regimen for M. avium complex infection has not been established. Clarithromycin is accepted as the cornerstone drug for treatment of M. avium lung disease; however, good model systems, especially animal models, are needed to evaluate the most effective companion drugs. We performed a series of experiments to evaluate and use different mouse models (comparing BALB/c, C57BL/6, nude, and beige mice) of M. avium infection and to assess the anti-M. avium activity of single and combination drug regimens, in vitro, ex vivo, and in mice. In vitro, clarithromycin and moxifloxacin were most active against M. avium, and no antagonism was observed between these two drugs. Nude mice were more susceptible to M. avium infection than the other mouse strains tested, but the impact of treatment was most clearly seen in M. avium-infected BALB/c mice. The combination of clarithromycin-ethambutol-rifampin was more effective in all infected mice than moxifloxacin-ethambutol-rifampin; the addition of moxifloxacin to the clarithromycin-containing regimen did not increase treatment efficacy. Clarithromycin-containing regimens are the most effective for M. avium infection; substitution of moxifloxacin for clarithromycin had a negative impact on treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.